Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 and up

Evaluating fecal microbiota transplantation for ulcerative colitis treatment

Official title: A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

Run by The University of Texas Health Science Center, Houston · NCT05786404 · Data updated 2026-11-12

This study is testing if a new treatment using fecal microbiota transplantation can help people with active ulcerative colitis feel better.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorThe University of Texas Health Science Center, Houston
Academic / other
Drugs / interventionschemotherapy, prednisone
Locations1 site (Houston, Texas)
StatusRecruiting
StartedDecember 15, 2023
Main results expectedDecember 15, 2026
Study endsDecember 15, 2027
Registry record updatedMay 10, 2024
Trial IDNCT05786404 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals diagnosed with active ulcerative colitis who meet specific clinical criteria.

Probably not a fit

Patients with severe ulcerative colitis or those unable to take retention enemas or capsules may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety, feasibility, and preliminary efficacy of fecal microbiota transplantation (FMT) in patients with active ulcerative colitis (UC). Participants will receive either frozen FMT via retention enema or lyophilized powder in oral capsules as an induction treatment. The study will also analyze changes in the microbiome, including diversity and specific genera, as well as the proportion of antibody-coated microbiota from baseline to post-treatment. The goal is to determine the effectiveness of microbiota replacement therapy in managing active UC.

Why it matters

Potential benefit: If successful, this treatment could provide a novel therapeutic option for patients suffering from active ulcerative colitis.

How similar studies have gone: Other studies have shown promise in using fecal microbiota transplantation for gastrointestinal conditions, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of active UC defined on clinical grounds (Partial Mayo score ≥ 3 with each subscore \>1)
* Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the study.
* Female subjects of childbearing potential must have a negative urine Qualitative Human Chorionic Gonadotropin(HCG)pregnancy test at enrolment and on the Week 1, Day 1 of the Treatment prior to administration of study drug.
* Willing and able to sign an informed consent form and attend all study-related clinic visits, assessments, and follow-up phone calls.
* Subject has an attending physician who will provide the non-FMT care.

Exclusion Criteria:

* Subjects with sever UC (Mayo score of \>7)
* Unable to take retention enema or multiple capsules orally.
* Females who are pregnant, breastfeeding, or planning to become pregnant during the study.
* Receipt of systemic non-topical antibiotics within 14 days of treatment day 1.
* Positive results for active HIV, Hepatitis B, or Hepatitis C infections.
* History of recurrent Clostridium difficile infection or FMT in the past 6-months.
* History of other active gastrointestinal conditions such as irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis etc.
* Known history of bile acid diarrhea
* Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone \>20 mg a day or prednisone-equivalent)
* History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted).
* History of use of an investigational drug within 90 days prior to the screening visit.
* History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives.
* Life expectancy of \< 1 year.
* In the opinion of investigator, subject for any reason, should be excluded from the study.
* Absolute neutrophil count (ANC) \< 500IU/mL

Where it's running

  • The University of Texas Health Science Center at Houston
    Houston, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Herbert L DuPont, MD — The University of Texas Health Science Center, Houston
  • Study coordinator: Herbert L DuPont, MD
  • Email: herbert.l.dupont@uth.tmc.edu
  • Phone: 713 500 6687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.